Sign In
×Competition Authority shows no objection to Dallah’s acquisition of 18.98% stake in IMCArgaam07/08/2022
Dallah Healthcare’s net profit set to surge in Q2 2022Argaam Special02/08/2022
Dallah to open board nominations on Aug. 1 Argaam31/07/2022
Dallah Healthcare’s net profit set to surge in Q2 2022Argaam Special02/08/2022
Osool & Bakheet issues Q2 2022 earnings forecasts for Saudi banks, firmsِArgaam special 06/07/2022
AlJazira Capital issues Q2 2022 forecasts for Saudi banks, firmsArgaam Special05/07/2022
Dallah Healthcare’s net profit set to surge in Q2 2022Argaam Special02/08/2022
Tadawul: These healthcare firms have highest leverage levelsArgaam Special27/07/2022
Overview of Tadawul-listed healthcare firms Q1 2022 performance, bed capacity plansArgaam Special22/06/2022
Overview of Dallah Healthcare’s Q1 2022 financials, equity investmentsArgaam Special07/06/2022
Here are details of Tadawul-listed healthcare firms’ Q4 2021 performance; bed capacity plans Argaam Special26/04/2022
Market Data
Last Trade | 119.00 |
Change | (0.20) |
Change (%) | (0.17) |
Open | 119.20 |
Low | 117.00 |
High | 121.00 |
Prev. Close | 119.20 |
Change (3M) | (2.14 %) |
Change (6M) | 43.20 % |
Volume | 53,980 |
Turnover | 6,423,178.00 |
Transactions | 474 |
Market Value | 10,710.00 |
Avg. Volume (3M) | 139,847.42 |
Avg. Turnover (3M) | 15,890,473.39 |
Avg. Transaction (3M) | 638.81 |
Change(12M) | 58.03 % |
YTD | 58.46 % |
Current | |
Market Cap (M SAR) | 10,710.00 |
Shares Outstanding ((M)) | 90.00 |
EPS ( | ) (TTM)3.21 |
Book Value (BV) ( SAR) (Latest announcement) | 21.70 |
Adjusted P/E (Last12) | 38.44 |
Price/book | 5.48 |
Dividend Yield (%) (Last Year) | 1.26 |
Return on Average Assets (%) (TTM) | 6.59 |
Return on Average Equity (%) (TTM) | 15.42 |
Enterprise Value (EV) (M) | 12,649.76 |
Event Date
|
Event
|
Venue
|
|
---|---|---|---|
12-06-2022
|
General Assembly | - | |
30-12-2021
|
Cash Dividend Distribution | - | |
16-12-2021
|
Ex-dividend Date | - | |
14-10-2021
|
Cash Dividend Distribution | - | |
30-09-2021
|
Ex-dividend Date | - | |
more |
Date | Research firm | Rating | Target Price | Link |
|
AlJazira Capital | Neutral | 117.00 | |
|
AlphaMena | Sell | 88.00 | |
|
Goldman Sachs | Buy | 126.00 | |
|
AlphaMena | Sell | 73.80 |

Call Request